Login or sign up
For business

Trigr Therapeutics

4.1· 8 reviews
Average ratingGreat
4.1/ 5

Based on 8 reviews

538%
438%
325%
20%
10%
Ask AI

Ask Trustburn about Trigr Therapeutics

Based on 8 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Avery Dale
Reviews 1

I recently had a fantastic experience with a therapeutic company. The level of service and care provided by the team was truly exceptional. The staff members were attentive, knowledgeable, and friendly. The overall experience exceeded my expectations, and I would highly recommend their services to anyone in need.

Arthur Tucker
Reviews 1

Trigr Therapeutics exceeded my expectations! Their staff is friendly, knowledgeable, and compassionate. The treatment options they offer are top-notch and have greatly improved my overall well-being. I would highly recommend Trigr Therapeutics to anyone in need.

Suprotek Ijpc
Reviews 1

Trigr Therapeutics has provided me with a great experience. The team is highly professional and knowledgeable. They were able to address all of my concerns and provide me with the best treatment options. I would highly recommend Trigr Therapeutics to anyone in need of their services.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Trigr Therapeutics

TRIGR Therapeutics is a privately-owned company focused on the development and commercialization of novel therapeutics for unmet medical needs. The company's immunotherapy pre-clinical pipeline consists of off the shelf products in contrast to CAR-T and other cellular processes which have delivered impressive clinical results while requiring complicated manufacturing processes and lead time to treat patients.

TRIGR is building an asset portfolio of clinical-stage and pre-clinical antibodies that will represent the next wave in cancer immunotherapy. they currently have partnered with innovative R&D companies, such as ABL Bio in South Korea, and will develop selected ABL programs into approved immunotherapies worldwide. TRIGR’s diversified pipeline currently consists of immunotherapies against novel and validated targets that have the potential to overcome and modulate biological barriers (e.g. tumor micro-environment) to result in successful treatment outcomes.